The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer’s disease

Alzheimer’s Research & Therapy

Eric M. Reiman¹  Kathryn V. Papp²  Rebecca E. Amariglio²  Keith A. Johnson²  Reisa A. Sperling²  Dorene M. Rentz²  Justin S. Sanchez³  Clara Vila-Castelar⁴  Edmarie Guzmán-Vélez⁴  Nathalia Muñoz⁴  Yakeel T. Quiroz⁴  Yamile Bocanegra⁵  Ana Baena⁵  Francisco Lopera⁵ 

[1] Banner Alzheimer’s Institute;Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School;Department of Neurology, Massachusetts General Hospital, Harvard Medical School;Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School;Grupo de Neurociencias de Antioquia, Universidad de Antioquia;

关键词: Alzheimer’s disease;    Autosomal dominant Alzheimer’s disease;    Neuropsychology;    Associative memory;    Imaging;    PET;   

DOI  :  10.1186/s13195-020-00671-w

来源: DOAJ

【 摘 要 】

Abstract Background To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzheimer’s disease mutation (E280A) in Presenilin-1, who are genetically determined to develop early-onset dementia, from matched non-carriers. We also sought to examine whether LAS-FNAME performance is associated with amyloid-β and regional tau burden in mutation carriers. Methods A total of 35 cognitively intact mutation carriers (age range 26–41), 19 symptomatic carriers, and 48 matched non-carriers (age range 27–44) completed a neuropsychological assessment including the LAS-FNAME. A subset of participants (31 carriers [12 symptomatic] and 35 non-carriers) traveled from Colombia to Boston to undergo positron emission tomography (PET) using Pittsburgh compound B to measure mean cortical amyloid-β and flortaucipir for regional tau. ANOVA analyses and Spearman correlations were used to examine group differences and relationships among LAS-FNAME performance and amyloid-β and tau accumulation. Results Compared to non-carriers, cognitively intact mutation carriers had lower scores on the LAS-FNAME Total Scores (p = .040). Across all carriers (including symptomatic carriers), higher levels of amyloid-β (r = − .436, p = .018) and regional tau in the entorhinal (r = − .394, p = .031) and inferior temporal cortex (r = − .563, p = .001) were associated with lower LAS-FNAME Total Scores. Conclusions Performance on the LAS-FNAME differentiated between cognitively intact mutation carriers from non-carriers and was associated with greater amyloid and tau burden when examining all carriers. Findings suggest that the LAS-FNAME is sensitive to early clinical and pathological changes and can potentially help track disease progression in Spanish-speaking individuals.

【 授权许可】

Unknown